FDA, Industry Unveil Mechanistic Trial Simulation Models
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA partnered with industry to create four trial simulation models for Parkinson's disease, diabetes, depression and measuring cancer progression, which were unveiled at the Jan. 24-25 Drug Industry Association meeting on "Sharing Knowledge To Improve Clinical Drug Development and Regulatory Decisions.
You may also be interested in...
Otitis Media Studies Can Use Four Trial Designs Under FDA Draft Guidance
FDA's draft guidance for developing drugs to treat acute bacterial otitis media offers sponsors four possible superiority study designs
Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs
Every month, Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA’s own review documents, including the discipline reviews, decision memos, meeting minutes, emails, and other documents, we strive to illuminate the agency decision-making process.
Otitis Media Studies Can Use Four Trial Designs Under FDA Draft Guidance
FDA's draft guidance for developing drugs to treat acute bacterial otitis media offers sponsors four possible superiority study designs